🟢 Tscan Therapeutics is trading 7.5% up in pre-market

Tscan Therapeutics is trading 7.5% up at $0.35 in pre-market, with no clear catalyst identified.

• No major company-specific announcement dated September 10, 2026, was identified.
• The latest significant update, dated September 2, involved a strategic reorganization, an approximately 75% workforce reduction, and a shift toward in vivo solid-tumor programs; that news is stale.
• Broader markets are weaker ahead of inflation data, making the gain difficult to attribute to macro sentiment.